Open AccessBiomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer
Author(s) -
Mitch Dowsett,
Lucy Kilburn,
Mothaffar F. Rimawi,
C. Kent Osborne,
Katherine L. Pogue–Geile,
Yuan Liu,
Samuel A. Jacobs,
Melanie Finnigan,
Shan Puhalla,
Andrew Dodson,
Vera Martins,
Maggie C.U. Cheang,
Sophie Perry,
Chris Holcombe,
Nicholas C. Turner,
Claire Swift,
Judith Bliss,
Stephen Johnston
Publication year - 2021
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-21-1628
Subject(s) - palbociclib , letrozole , medicine , breast cancer , oncology , cancer , metastatic breast cancer , tamoxifen
To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER + /HER2 - breast cancer; and (ii) the pharmacodynamic effect of the agents on the biomarkers.